LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Recursion Pharmaceuticals Inc

Închisă

SectorSănătate

4.56 7.55

Rezumat

Modificarea prețului

24h

Curent

Minim

4.25

Maxim

4.63

Indicatori cheie

By Trading Economics

Venit

-24M

-202M

Vânzări

10M

15M

EPS

-0.5

Marjă de profit

-1,373.259

Angajați

800

EBITDA

-26M

-191M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+56.61% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-431M

1.9B

Deschiderea anterioară

-2.99

Închiderea anterioară

4.56

Sentimentul știrilor

By Acuity

100%

0%

371 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 mai 2025, 22:52 UTC

Câștiguri
Principalele dinamici ale pieței

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 mai 2025, 20:37 UTC

Top știri
Câștiguri

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 mai 2025, 23:14 UTC

Top știri

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 mai 2025, 22:46 UTC

Top știri
Achiziții, Fuziuni, Preluări

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 21:58 UTC

Câștiguri

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 mai 2025, 21:24 UTC

Câștiguri

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 mai 2025, 20:54 UTC

Market Talk
Câștiguri

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 mai 2025, 20:54 UTC

Câștiguri

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 mai 2025, 20:51 UTC

Câștiguri

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 mai 2025, 20:50 UTC

Achiziții, Fuziuni, Preluări

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 mai 2025, 20:50 UTC

Câștiguri

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 mai 2025, 20:26 UTC

Top știri

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 mai 2025, 20:25 UTC

Câștiguri

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparație

Modificare preț

Recursion Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

56.61% sus

Prognoză pe 12 luni

Medie 6.75 USD  56.61%

Maxim 8 USD

Minim 3 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRecursion Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.15 / 4.75Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

371 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.